Facet Life Sciences Forms Strategic Partnership with Nucleus
Facet Life Sciences is a highly regarded entity in the life sciences sector, guiding companies through the intricate maze of drug and medical device development. The firm is excited to introduce its collaboration as the official regulatory partner of Nucleus, a prominent innovator in diagnostic and therapeutic radiopharmaceuticals. This partnership signifies Facet's commitment to enhancing the regulatory landscape in the radiopharmaceutical domain.
Collaboration Aimed at Regulatory Excellence
Ken VanLuvanee, the President and CEO of Facet Life Sciences, expressed enthusiasm about this collaboration. He emphasized their extensive expertise in regulatory strategy and medical writing, which are vital for smooth FDA interactions. The partnership aims to advance innovative radiopharmaceutical products, helping Nucleus and its clientele navigate their FDA journeys.
Expertise in Radiopharmaceuticals
Facet Life Sciences boasts an impressive track record, having orchestrated over 40 IND, NDA, BLA, and ANDA applications to the FDA. The team has led more than 75 meetings with diverse FDA divisions, such as CDER, CBER, and OGD. Facet's expertise places them among the recognized leaders in the realm of regulatory affairs focused on diagnostic and therapeutic radiopharmaceuticals. This proficiency positions them as an invaluable resource for Nucleus, allowing effective navigation through the complexities of FDA approval.
About Facet Life Sciences
Facet Life Sciences excels in offering tailored regulatory solutions for drug, biologic, and medical device development. The company's team consists of over 20 seasoned professionals, each having more than 15 years of experience with the FDA. They pride themselves on delivering effective, cost-efficient strategies that address the unique challenges faced during the FDA process. For more insights into their services, visit their official website.
About Nucleus Radiopharma
Nucleus RadioPharma is a cutting-edge Contract Development and Manufacturing Organization (CDMO) focusing on targeted radiotherapies. It offers a comprehensive range of services, including formulation, analytical development, and regulatory documentation. Nucleus employs advanced technology platforms to drive radiopharmaceutical research, guiding new therapies from clinical trials to market readiness. Their commitment to quality positions them at the forefront of the industry.
Frequently Asked Questions
What is the focus of Facet Life Sciences?
Facet Life Sciences specializes in assisting life science companies with drug, biologic, and medical device regulatory processes.
What is Facet's relationship with Nucleus?
Facet serves as the official regulatory partner for Nucleus, helping them with FDA-related regulatory challenges.
How many applications has Facet submitted to the FDA?
Facet has submitted over 40 IND, NDA, BLA, and ANDA applications to the FDA, showcasing their extensive experience.
Who leads Facet Life Sciences?
The company is led by Ken VanLuvanee, who emphasizes regulatory expertise and knowledge in their service offerings.
What services does Nucleus provide?
Nucleus offers drug development services, regulatory documentation, and manufacturing of targeted radiotherapies, ensuring quality and innovation.
